Prof. Dr. med. Peter Effert

Publikationen

Effert, P., Frye, R., Neubauer, A., Liu, E., Walther, P.: Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: Analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J. Urol., 147: 192-196, 1992.

Effert, P., Neubauer, A., Walther, P., Liu, E.: Alterations of the p53 gene are involved in the progression of a human prostate carcinoma. J. Urol., 147: 789-793, 1992.

Neubauer, A., Neubauer, B., He, M., Effert, P., Iglehart, D., Frye, R., Liu, E.: Technical report: Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene, 7: 1019-1025, 1992.

Wiener, J., Effert, P., Humphrey, P., Liu, E., Walther, P.: Prevalence of human papillomavirus types 16 and 18 in squamous cell carcinoma of the penis: A retrospective analysis of primary and metastatic lesions by differential polymerase chain reaction. Int. J. Cancer, 50: 694-701, 1992.

Effert, P., Liu, E., Raab-Traub, N.: Alterations of the p53 gene in nasopharyngeal carcinoma. J. Virol., 66, 3768-3775, 1992.

Levendakou, E., Strohmeyer, T., Effert, P., Walther, P., Liu, E.: Expression of the Matrix-GIa protein in urogenital malignancies. Int. J. Cancer, 52, 534-537, 1992.

Effert, P., Ackermann, R.: Clinical manifestation and indication for therapy in benign prostatic hyperplasia. Urologe A, 31, 135-141, 1992.

Effert, P., McCoy, R., Walther, P., Liu, E.: P53 gene alterations in human prostate carcinoma. J. Urol., 150, 257-261, 1993.

Strohmeyer, T., Effert, P.: Das Prostatakarzinom: Zytogenetische und molekularbiologische Grundlagen. Med. Klinik, 88, 482-484, 1993.

Boeckmann, W., Effert, P., Wolff, J.M., Jakse, G.: Laparoscopic pelvic lymphadenectomy. Acta Urol Belg 62: 45-50, 1994.

Effert, P., Strohmeyer, T.: Basic research in prostate cancer: Molecular Biology. Acta Urol Belg 62: 15-21, 1994.

Wolff, J.M., Boeckmann, W., Effert, P., Handt, S., Jakse, G.: Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Br. J. Urol.: 76, 41-46, 1995.

Effert, P., Strohmeyer, T.: Theories on the metastatic process and possible therapeutic options. Urol. Res. 23: 11-19, 1995.

Effert, P., Wendt, G., Handt, S., Wolff, J.M., Keulers, R., Jakse, G.: Direct invasion of the renal vein by metastatic testicular cancer. Europ. Urol. 31(1): 119-121, 1997

Effert, P., Gastl, G., Strohmeyer, G.: Current and future strategies to block tumor angiogenesis, invasion and metastasis. World J. Urol.14: 131-140, 1996.

Effert, P., Bares, R., Handt, S., Wolff, J., Büll, U., Jakse, G.: Metabolic imaging of untreated prostate cancer by positron emission tomography with fluorine-18-labeled deoxyglucose (FDG-PET). J. Urol. 155(3): 994-998, 1996.

Boeckmann, W., Wolff, J., Adam, G., Effert, P., Jakse, G.: Laparoscopic bilateral ureterolysis in Ormond`s disease. Urol Int 56: 133-136, 1996.

Wolff, J., Borchers, H., Effert, P., Habib, F., Jakse, G.: Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia. Br. J. Urol. 78: 409-413, 1996.

Effert, P., Boeckmann, W., Wolff, J., Jakse, G.: Laparoscopic pelvic lymphadenectomy in prostate cancer: results in 120 patients. Urologe A 35: 413-417, 1996.

Planz, B., Striepecke, E., Wolf J.M., Effert, P., Jakse, G., Boecking A.: DANA-aneuploidy as marker for neoplasia in G1-urothelial carcinomas. Gen. Diagn. Pathol. 142(2): 69-73, 1996.

Wolff, J., Boeckmann, W., Effert, P., Handt, S., Jakse, G.: Clinical use of prostatespecific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate. Eur Urol 30(4): 451-457, 1996

Schorn, H., Boeckmann, W., Wolff, J.M., Effert, P., Jakse, G.: Genital self-mutilation: sub-preputial space- the final frontier? Br. J. Urol.: 78(6):949-950, 1996.

Wolff, J.M., Boeckmann, W., Effert, P., Habib, F.K., Jakse, G.: Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA. Anticancer Res. 17(4B): 2993-2994, 1997

Cremerius U., Effert, P., Adam, G., Sabri, O., Zimmy, M., Wagenknecht, G., Jakse, G., Buell, U.: FDG PET for detection and therapy control of metastatic germ cell tumor. J. Nucl. Med.: 39(5): 815-822, 1998.

Fuzesi, L., Gunawan, B., Braun, S., Bergmann, F., Brauers, A., Effert, P., Mittermayer, C.: Cytogenetic analysis of 11 renal oncocytomas: further evidence of structural rearrangements of 11q13 as a characteristic chromosomal anomaly. Cancer Genet Cytogenet 107(1): 1-6, 1998.

Effert, P.: Notfälle in der Urologie. Medizin im Bild 2: 14-17, 1998.

Effert, P., Röttger, P., Steffens, J.: Das zystische Nephrom. Urologe B 39: 499-501, 1999.

Thiel, R., Effert, P.: Primary adenocarcinoma of the seminal vesicles. J. Urol. 168: 1891-1896, 2002.

Seifert, P., Benedic, M., Effert, P.: Nerve fibers in tumors of the human urinary bladder. Virchows Arch (Germany) 440(3): 291-297, 2002.

Effert, P., Hillger, H.: Gute Erfahrungen mit Estramustinphosphat in der Second-line-Therapie. Uro News 1: 1- 3, 2003

Effert, P., Seifert, P.: Invasive poten tial of „noninvasive“ human bladder carcinoma: An electron microscopy study. Am J Clin Pathol 120: 188-193, 2003

Thiel, R., Effert, P., Konrad, G.: Primäres Samenblasenkarzinom- Was muss der Urologe wissen? Extracta urologica 10: 15-17, 2003

Strohmeyer D., Peschel R., Effert, P., Borchert, O., Janetschek, G., Bartsch, G., Frauscher, F.: Changes of renal blood flow in nephroptosis: Assessment by color doppler imaging, isotope renography and correlation with clinical outcome after laparoscopic nephropexy. Eur Urol, accepted for publication

Vögeli, T., Kurz, A., Grimm, O., Effert, P., Eckardt K.: Anemia under androgen deprivation: Influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system. Europ Urol – submitted for publication

Strohmeyer, D., Strauß, F., Rössing, Ch., Roberts, Ch., Kaufman, O., Bartsch, G., Effert, P.: Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res – submitted for publication